Suppr超能文献

应用分段血浆分离和吸附(Prometheus®)治疗鹅膏蕈中毒。

Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®).

机构信息

Department of Internal Medicine 1, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

出版信息

J Gastrointestin Liver Dis. 2012 Jun;21(2):171-6.

Abstract

OBJECTIVE

To investigate the effectiveness and safety of extracorporeal detoxification using the fractionated plasma separation and adsorption system (FPSA, Prometheus® 4008H, Fresenius Medical Care, Germany) in patients suffering from acute liver failure due to intoxication with Amanita phalloides (AP) toxin.

METHODS

The study population consisted of 20 patients with proven AP intoxication (FPSA treatment group n=9, control group n=11). Urinary amanitin toxin concentration was measured by the Amanitin ELISA Kit (Bühlmann Laboratories, Germany, cut off level 1.5 ng/ml). All patients received standard medical treatment with activated charcoal, i.v. crystalloid fluids, silibinine and N-acetylcysteine. Additionally 9 patients underwent treatment with FPSA until undetectable amanitin levels.

RESULTS

Mean urinary amanitin levels were significantly reduced by FPSA with 42.5 +/- 21.9 ng/ml before and 1.2 +/- 0.31 ng/ml after treatment (p=0.04). No hemodynamic, respiratory or hematological complications were observed. None of the patients had to undergo liver transplantation. All patients in the treatment group survived and were discharged fully recovered. One patient in the control group died due to shock and lactic acidosis; one patient remained dialysis dependent. Mean duration of hospital stay was 7.1 days in the treatment group and 11.7 days in the control group (p=0.30).

CONCLUSIONS

Use of liver support therapy by fractionated plasma separation and adsorption (Prometheus®) offers a safe way for elimination of Amanita toxin with the potential to avoid the need for liver transplantation.

摘要

目的

研究使用分段血浆分离和吸附系统(FPSA,Prometheus®4008H,Fresenius Medical Care,德国)对毒蕈碱(AP)毒素中毒引起的急性肝衰竭患者进行体外解毒的有效性和安全性。

方法

研究人群包括 20 例经证实的 AP 中毒患者(FPSA 治疗组 n=9,对照组 n=11)。尿鹅膏蕈碱毒素浓度采用鹅膏蕈碱 ELISA 试剂盒(Bühlmann Laboratories,德国,截断值 1.5ng/ml)进行测量。所有患者均接受标准治疗,包括活性炭、静脉晶体液、水飞蓟宾和 N-乙酰半胱氨酸。此外,9 例患者接受 FPSA 治疗,直至鹅膏蕈碱水平无法检测到。

结果

FPSA 治疗后,平均尿鹅膏蕈碱水平显著降低,治疗前为 42.5+/-21.9ng/ml,治疗后为 1.2+/-0.31ng/ml(p=0.04)。未观察到血液动力学、呼吸或血液学并发症。无患者需要进行肝移植。治疗组所有患者均存活并完全康复出院。对照组 1 例患者因休克和乳酸性酸中毒死亡,1 例患者仍依赖透析。治疗组的平均住院时间为 7.1 天,对照组为 11.7 天(p=0.30)。

结论

使用分段血浆分离和吸附(Prometheus®)进行肝脏支持治疗是消除鹅膏蕈碱毒素的一种安全方法,有可能避免肝移植的需要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验